{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:24:59Z","timestamp":1787181899410,"version":"build-2736575974"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003835","name":"I-Shou University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003835","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119814","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:01:08Z","timestamp":1785805268000},"page":"119814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The estrogen-integrin \u03b1v\u03b23 crosstalk in breast cancer: Modulating PD-L1 and immune evasion"],"prefix":"10.1016","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1612-924X","authenticated-orcid":false,"given":"Dana R.","family":"Crawford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Ning","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Cheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Mao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen S.H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Jung","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Ku","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Jung","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Yun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biopha.2026.119814_bib1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000464353","article-title":"PD-1\/PD-L1 pathway in breast cancer","volume":"40","author":"Sch\u00fctz","year":"2017","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.biopha.2026.119814_bib2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.semcancer.2019.12.003","article-title":"PD-L1 status in breast cancer: current view and perspectives","volume":"72","author":"Vranic","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119814_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081830","article-title":"NDAT targets PI3K-mediated PD-L1 upregulation to reduce proliferation in gefitinib-resistant colorectal cancer","volume":"9","author":"Huang","year":"2020","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.biopha.2026.119814_bib4","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1007\/s00432-021-03694-4","article-title":"Inhibitors of PD-1\/PD-L1 and ERK1\/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines","volume":"147","author":"Br\u00e4utigam","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119814_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.568931","article-title":"The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment","volume":"11","author":"Hudson","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119814_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111436","article-title":"PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines","volume":"138","author":"Lotfinejad","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"40","key":"10.1016\/j.biopha.2026.119814_bib7","doi-asserted-by":"crossref","first-page":"20141","DOI":"10.1073\/pnas.1901931116","article-title":"\u03b1v\u03b23-integrin regulates PD-L1 expression and is involved in cancer immune evasion","volume":"116","author":"Vannini","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"19","key":"10.1016\/j.biopha.2026.119814_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cells11193050","article-title":"Thyroid hormone induces oral cancer growth via the PD-L1-dependent signaling pathway","volume":"11","author":"Su","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.biopha.2026.119814_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/294278","article-title":"Sex hormones and their receptors regulate liver energy homeostasis","volume":"2015","author":"Shen","year":"2015","journal-title":"Int. J. Endocrinol."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119814_bib11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jnr.23809","article-title":"Understanding the broad influence of sex hormones and sex differences in the brain","volume":"95","author":"McEwen","year":"2017","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.biopha.2026.119814_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.672853","article-title":"Regulation of the immune system development by glucocorticoids and sex hormones","volume":"12","author":"Quatrini","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119814_bib13","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/654698","article-title":"Role of estrogen receptor signaling in breast cancer metastasis","volume":"2012","author":"Saha Roy","year":"2012","journal-title":"Int. J. Breast Cancer"},{"key":"10.1016\/j.biopha.2026.119814_bib14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40164-018-0116-7","article-title":"Mechanisms for estrogen receptor expression in human cancer","volume":"7","author":"Hua","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbrc.2018.09.005","article-title":"ER\u03b1 is a negative regulator of PD-L1 gene transcription in breast cancer","volume":"505","author":"Liu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2026.119814_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.836417","article-title":"Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence","volume":"9","author":"Almansour","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12929-022-00816-z","article-title":"The power of heteronemin in cancers","volume":"29","author":"Wang","year":"2022","journal-title":"J. Biomed. Sci."},{"issue":"17","key":"10.1016\/j.biopha.2026.119814_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cells12172126","article-title":"Integrins and actions of androgen in breast cancer","volume":"12","author":"Tsai","year":"2023","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.biopha.2026.119814_bib19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.biopha.2026.119814_bib20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1042\/bst0280311","article-title":"Integrin structure","volume":"28","author":"Humphries","year":"2000","journal-title":"Biochem. Soc. Trans."},{"issue":"6","key":"10.1016\/j.biopha.2026.119814_bib21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2026.119814_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/gb-2007-8-5-215","article-title":"The integrins","volume":"8","author":"Takada","year":"2007","journal-title":"Genome Biol."},{"issue":"25","key":"10.1016\/j.biopha.2026.119814_bib24","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1038\/onc.2012.320","article-title":"Integrin \u03b25 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways","volume":"32","author":"Bianchi-Smiraglia","year":"2013","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.biopha.2026.119814_bib25","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.259465","article-title":"Molecular determinants of \u03b1V\u03b25 localization in flat clathrin lattices - role of \u03b1V\u03b25 in cell adhesion and proliferation","volume":"135","author":"Zuidema","year":"2022","journal-title":"J. Cell. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2026.119814_bib26","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.3892\/mmr.2014.3140","article-title":"Integrin \u03b1v\u03b23 is required for cathepsin B-induced hepatocellular carcinoma progression","volume":"11","author":"Xu","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12929-021-00719-5","article-title":"Role of thyroid hormone-integrin \u03b1v\u03b23-signal and therapeutic strategies in colorectal cancers","volume":"28","author":"Yang","year":"2021","journal-title":"J. Biomed. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2026.119814_bib28","article-title":"Evaluation of serum integrin \u03b1v\u03b23 & vitronectin in the early diagnosis of breast cancer","volume":"65","author":"Radwan","year":"2019","journal-title":"Clin. Lab."},{"key":"10.1016\/j.biopha.2026.119814_bib29","article-title":"Role of integrin \u03b1v\u03b23 in doxycycline-induced anti-proliferation in breast cancer cells","volume":"10","author":"Chen","year":"2022","journal-title":"Front. Cell. Dev. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119814_bib30","first-page":"839","article-title":"Depletion of CCN1\/CYR61 reduces triple-negative\/basal-like breast cancer aggressiveness","volume":"12","author":"Espinoza","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"15","key":"10.1016\/j.biopha.2026.119814_bib31","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41388-021-01731-7","article-title":"CTGF regulates cell proliferation, migration, and glucose metabolism through activation of FAK signaling in triple-negative breast cancer","volume":"40","author":"Kim","year":"2021","journal-title":"Oncogene"},{"issue":"34","key":"10.1016\/j.biopha.2026.119814_bib32","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1038\/s41388-022-02409-4","article-title":"Autocrine pro-legumain promotes breast cancer metastasis via binding to integrin \u03b1v\u03b23","volume":"41","author":"Liu","year":"2022","journal-title":"Oncogene"},{"issue":"28","key":"10.1016\/j.biopha.2026.119814_bib33","doi-asserted-by":"crossref","first-page":"21526","DOI":"10.1074\/jbc.M110.129999","article-title":"Knock-in mutation reveals an essential role for focal adhesion kinase activity in blood vessel morphogenesis and cell motility-polarity but not cell proliferation","volume":"285","author":"Lim","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2026.119814_bib34","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nrm1490","article-title":"Integrin signalling during tumour progression","volume":"5","author":"Guo","year":"2004","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13046-019-1056-8","article-title":"Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells","volume":"38","author":"Rigiracciolo","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.biopha.2026.119814_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cells14221832","article-title":"Integrin \u03b1v\u03b23 as a non-genomic estrogen receptor in breast cancer for signaling pathways and crosstalk","volume":"14","author":"Wang","year":"2025","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.biopha.2026.119814_bib37","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1152\/japplphysiol.00994.2009","article-title":"Signaling responses after exposure to 5 alpha-dihydrotestosterone or 17 beta-estradiol in norepinephrine-induced hypertrophy of neonatal rat ventricular myocytes","volume":"108","author":"Koshman","year":"2010","journal-title":"J. Appl. Physiol."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119814_bib38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2119\/2006-00083.Kallergi","article-title":"Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells","volume":"13","author":"Kallergi","year":"2007","journal-title":"Mol. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119814_bib39","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1159\/000110458","article-title":"Activation of FAK\/PI3K\/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells","volume":"20","author":"Kallergi","year":"2007","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.biopha.2026.119814_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.628690","article-title":"Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast cancer","volume":"12","author":"Dong","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119814_bib41","first-page":"2699","article-title":"Focal adhesion kinase enhances signaling through the Shc\/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples","volume":"62","author":"Hecker","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119814_bib42","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fimmu.2019.02022","article-title":"PD-L1 Distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition","volume":"10","author":"Wu","year":"2019","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119814_bib43","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/IGC.0000000000000875","article-title":"Posttranscriptional control of PD-L1 expression by 17\u03b2-estradiol via PI3K\/Akt signaling pathway in ER\u03b1-positive cancer cell lines","volume":"27","author":"Yang","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2026.119814_bib44","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1016\/j.apsb.2021.03.010","article-title":"PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma","volume":"11","author":"Luo","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2026.119814_bib45","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-018-0022-9","article-title":"The intracellular signalosome of PD-L1 in cancer cells","volume":"3","author":"Escors","year":"2018","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib46","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1038\/s41598-024-51804-2","article-title":"Investigation of the potential effects of estrogen receptor modulators on immune checkpoint molecules","volume":"14","author":"Abramenko","year":"2024","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2026.119814_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088557","article-title":"PD-L1 expression is increased in a subset of basal type breast cancer cells","volume":"9","author":"Soliman","year":"2014","journal-title":"PLOS One"},{"issue":"7","key":"10.1016\/j.biopha.2026.119814_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076420","article-title":"PD-1 independent role of PD-L1 in triple-negative breast cancer progression","volume":"24","author":"Alkaabi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.biopha.2026.119814_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184479","article-title":"Tumor infiltrating lymphocytes (TILS) and PD-L1 expression in breast cancer: a review of current evidence and prognostic implications from pathologist's perspective","volume":"15","author":"Angelico","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.biopha.2026.119814_bib50","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nomi","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119814_bib51","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"10.1016\/j.biopha.2026.119814_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1330","article-title":"17-\u03b2-estradiol reduces surface PD-L1 expression in estrogen receptor-positive breast cancer but not type 1 endometrial cancer cells","volume":"13","author":"Li","year":"2023","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib53","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cmet.2020.10.021","article-title":"NAD(+) metabolism maintains inducible PD-L1 expression to drive tumor immune evasion","volume":"33","author":"Lv","year":"2021","journal-title":"Cell. Metab."},{"issue":"2","key":"10.1016\/j.biopha.2026.119814_bib54","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41388-018-0502-y","article-title":"Correction: the atypical ubiquitin ligase RNF31 stabilizes estrogen receptor \u03b1 and modulates estrogen-stimulated breast cancer cell proliferation","volume":"38","author":"Zhu","year":"2019","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib55","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s13046-022-02576-y","article-title":"RNF31 represses cell progression and immune evasion via YAP\/PD-L1 suppression in triple negative breast Cancer","volume":"41","author":"Yang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2026.119814_bib56","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41388-023-02592-y","article-title":"NAD(+) supplementation limits triple-negative breast cancer metastasis via SIRT1-P66Shc signaling","volume":"42","author":"Jiang","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2026.119814_bib57","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.steroids.2016.05.006","article-title":"Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells","volume":"114","author":"Lin","year":"2016","journal-title":"Steroids"},{"issue":"5","key":"10.1016\/j.biopha.2026.119814_bib58","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/ERC-17-0376","article-title":"Thyroxine inhibits resveratrol-caused apoptosis by PD-L1 in ovarian cancer cells","volume":"25","author":"Chin","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.biopha.2026.119814_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.582863","article-title":"Estrogen receptor downregulates expression of PD-1\/PD-L1 and infiltration of CD8(+) T cells by inhibiting IL-17 signaling transduction in breast cancer","volume":"10","author":"Shuai","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib60","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/1878-0261.13083","article-title":"Prolonged estrogen deprivation triggers a broad immunosuppressive phenotype in breast cancer cells","volume":"16","author":"H\u00fchn","year":"2022","journal-title":"Mol. Oncol."},{"issue":"34","key":"10.1016\/j.biopha.2026.119814_bib61","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1038\/onc.2013.573","article-title":"The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor \u03b1 and modulates estrogen-stimulated breast cancer cell proliferation","volume":"33","author":"Zhu","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2026.119814_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2022.106314","article-title":"YB-1 promotes cell proliferation and metastasis by targeting cell-intrinsic PD-1\/PD-L1 pathway in breast cancer","volume":"153","author":"Wu","year":"2022","journal-title":"Int. J. Biochem. Cell. Biol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119814_bib63","first-page":"1611","article-title":"The oncogenic roles and clinical implications of YAP\/TAZ in breast cancer","volume":"128","author":"Luo","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2026.119814_bib64","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41551-025-01357-0","article-title":"Identifying perturbations that boost T-cell infiltration into tumours via counterfactual learning of their spatial proteomic profiles","volume":"9","author":"Wang","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"5","key":"10.1016\/j.biopha.2026.119814_bib65","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/cas.15326","article-title":"Deubiquitinase ubiquitin-specific peptidase 10 maintains cysteine rich angiogenic inducer 61 expression via Yes1 associated transcriptional regulator to augment immune escape and metastasis of pancreatic adenocarcinoma","volume":"113","author":"Liu","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2026.119814_bib66","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.17629","article-title":"Prognostic and therapeutic insights into colorectal carcinoma through immunogenic cell death gene profiling","volume":"12","author":"Yu","year":"2024","journal-title":"PeerJ"},{"key":"10.1016\/j.biopha.2026.119814_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1297116","article-title":"p66Shc deficiency in CLL cells enhances PD-L1 expression and suppresses immune synapse formation","volume":"12","author":"Lopresti","year":"2024","journal-title":"Front. Cell. Dev. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119814_bib68","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41401-021-00631-6","article-title":"The modulation of PD-L1 induced by the oncogenic HBXIP for breast cancer growth","volume":"43","author":"Xu","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.biopha.2026.119814_bib69","article-title":"Effect of estrogen on heteronemin-induced anti-proliferative effect in breast cancer cells with different estrogen receptor status","volume":"9","author":"Yang","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib70","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3892\/or.2014.3558","article-title":"Non-genomic actions of estradiol and 4-OH-tamoxifen on murine breast cancer cells","volume":"33","author":"Raffo","year":"2015","journal-title":"Oncol. Rep."},{"issue":"10","key":"10.1016\/j.biopha.2026.119814_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101479","article-title":"STAT3 activity promotes programmed-death ligand 1 expression and suppresses immune responses in breast cancer","volume":"11","author":"Zerdes","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib72","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1186\/s40064-016-2513-x","article-title":"PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker","volume":"5","author":"Guo","year":"2016","journal-title":"Springerplus"},{"issue":"28","key":"10.1016\/j.biopha.2026.119814_bib73","doi-asserted-by":"crossref","first-page":"26483","DOI":"10.18632\/oncotarget.4494","article-title":"Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer","volume":"6","author":"Barrett","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.biopha.2026.119814_bib74","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131458","article-title":"PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer","volume":"6","author":"Chen","year":"2021","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.biopha.2026.119814_bib75","doi-asserted-by":"crossref","first-page":"e1205","DOI":"10.1016\/j.clbc.2018.05.006","article-title":"JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple-negative breast cancer","volume":"18","author":"Chen","year":"2018","journal-title":"Clin. Breast Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib76","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13058-023-01684-7","article-title":"Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3\/AKT pathways","volume":"25","author":"Chuangchot","year":"2023","journal-title":"Breast Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2026.119814_bib77","doi-asserted-by":"crossref","first-page":"669","DOI":"10.20892\/j.issn.2095-3941.2021.0137","article-title":"Super-enhancer receives signals from the extracellular matrix to induce PD-L1-mediated immune evasion via integrin\/BRAF\/TAK1\/ERK\/ETV4 signaling","volume":"19","author":"Ma","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.biopha.2026.119814_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118239","article-title":"Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN\/PI3K\/AKT\/mTOR signaling pathway","volume":"259","author":"Dastmalchi","year":"2020","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib79","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1158\/0008-5472.CAN-17-1636","article-title":"MUC1-C induces PD-L1 and immune evasion in triple-negative breast cancer","volume":"78","author":"Maeda","year":"2018","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.biopha.2026.119814_bib80","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1158\/1541-7786.MCR-16-0233","article-title":"MUC1-C represses the crumbs complex polarity factor CRB3 and downregulates the hippo pathway","volume":"14","author":"Alam","year":"2016","journal-title":"Mol. Cancer Res."},{"issue":"7","key":"10.1016\/j.biopha.2026.119814_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2017.61","article-title":"Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells","volume":"6","author":"Huang","year":"2017","journal-title":"Oncogenesis"},{"issue":"11","key":"10.1016\/j.biopha.2026.119814_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113343","article-title":"PD-L1-mediated immune evasion in triple-negative breast cancer is linked to the loss of ZNF652","volume":"42","author":"Liu","year":"2023","journal-title":"Cell. Rep."},{"key":"10.1016\/j.biopha.2026.119814_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118939","article-title":"MicroRNA -383-5p restrains the proliferation and migration of breast cancer cells and promotes apoptosis via inhibition of PD-L1","volume":"267","author":"Azarbarzin","year":"2021","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.biopha.2026.119814_bib84","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10549-018-4833-8","article-title":"Syntenin1\/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1","volume":"171","author":"Liu","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.biopha.2026.119814_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112034","article-title":"BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer","volume":"392","author":"Jing","year":"2020","journal-title":"Exp. Cell. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13058-023-01606-7","article-title":"Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment","volume":"25","author":"Hanamura","year":"2023","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.biopha.2026.119814_bib87","doi-asserted-by":"crossref","DOI":"10.1038\/npjbcancer.2016.2","article-title":"Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer","volume":"2","author":"Tung","year":"2016","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2026.119814_bib88","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00441-021-03496-7","article-title":"Estrogen prevents cellular senescence and bone loss through Usp10-dependent p53 degradation in osteocytes and osteoblasts: the role of estrogen in bone cell senescence","volume":"386","author":"Wei","year":"2021","journal-title":"Cell. Tissue Res."},{"issue":"53","key":"10.1016\/j.biopha.2026.119814_bib89","doi-asserted-by":"crossref","first-page":"8178","DOI":"10.1038\/sj.onc.1205682","article-title":"Cyr61 promotes breast tumorigenesis and cancer progression","volume":"21","author":"Tsai","year":"2002","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.biopha.2026.119814_bib90","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.biopha.2026.119814_bib91","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib92","article-title":"Integrin \u03b1v\u03b23-dependent pathogenic effect and therapeutic effects of DL-N2 combined with EGFR inhibitors in pancreatic adenocarcinoma","volume":"24","author":"Li","year":"2026","journal-title":"J. Transl. Med."},{"issue":"31","key":"10.1016\/j.biopha.2026.119814_bib93","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1038\/onc.2015.476","article-title":"Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growth","volume":"35","author":"Li","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib94","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1038\/s41467-022-30831-5","article-title":"YAP inhibits ER\u03b1 and ER(+) breast cancer growth by disrupting a TEAD-ER\u03b1 signaling axis","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.biopha.2026.119814_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14112513","article-title":"Pheophorbide A-mediated photodynamic therapy potentiates checkpoint blockade therapy of tumor with low PD-L1 expression","volume":"14","author":"Tong","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119814_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121533","article-title":"A Sub-6 nm MnFe(2)O(4)-dichloroacetic acid nanocomposite modulates tumor metabolism and catabolism for reversing tumor immunosuppressive microenvironment and boosting immunotherapy","volume":"284","author":"Dai","year":"2022","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib97","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1038\/s41598-021-84492-3","article-title":"Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer","volume":"11","author":"De Vita","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib98","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1039\/C9BM01766F","article-title":"Leukocyte-mimicking nanovesicles for effective doxorubicin delivery to treat breast cancer and melanoma","volume":"8","author":"Molinaro","year":"2020","journal-title":"Biomater. Sci."},{"issue":"15","key":"10.1016\/j.biopha.2026.119814_bib99","doi-asserted-by":"crossref","first-page":"9436","DOI":"10.1039\/D4NR03907F","article-title":"Engineered anti-HER2 drug delivery nanosystems for the treatment of breast cancer","volume":"17","author":"Vanni","year":"2025","journal-title":"Nanoscale"},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","article-title":"Targeting integrin pathways: mechanisms and advances in therapy","volume":"8","author":"Pang","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119814_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106694","article-title":"The challenges and opportunities of \u03b1v\u03b23-based therapeutics in cancer: From bench to clinical trials","volume":"189","author":"Gu","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119814_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12061163","article-title":"The role of \u03b1v\u03b23 integrin in cancer therapy resistance","volume":"12","author":"Pachane","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.biopha.2026.119814_bib103","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/carcin\/bgaa092","article-title":"Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer","volume":"42","author":"Chatterjee","year":"2021","journal-title":"Carcinogenesis"},{"issue":"7","key":"10.1016\/j.biopha.2026.119814_bib104","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41419-020-2701-z","article-title":"PD-L1 promotes tumor growth and progression by activating WIP and \u03b2-catenin signaling pathways and predicts poor prognosis in lung cancer","volume":"11","author":"Yu","year":"2020","journal-title":"Cell. Death Dis."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:51:18Z","timestamp":1787179878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226008504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":104,"alternative-id":["S0753332226008504"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119814","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The estrogen-integrin \u03b1v\u03b23 crosstalk in breast cancer: Modulating PD-L1 and immune evasion","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119814","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119814"}}